Autoreactive T cells as potential targets for immunotherapy of autoimmune bullous skin diseases

Clinics in Dermatology

Volumn 19, Issue 5, 2001, Pages 592-597

  Hertl, Michael ^a   Riechers, Regine ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; T LYMPHOCYTE RECEPTOR;

ALLELE; AUTOIMMUNE DISEASE; BLISTER; BULLOUS SKIN DISEASE; HLA TYPING; HUMAN; IMMUNOGENETICS; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOGENESIS; MOUSE; NONHUMAN; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH2 CELL;

AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; PEMPHIGUS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SKIN DISEASES, VESICULOBULLOUS; T-LYMPHOCYTES;

EID: 0034804312     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(00)00171-1     Document Type: Review

References (43)

1. Management of the immunobullous disorders. II. Pemphigus
2. Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris
3. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris
4. Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients
5. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease
6. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic
7. Subclass distribution of human IgG autoantibodies in pemphigus
8. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris
9. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris; A model for autoimmunity
10. A case of pemphigus vulgaris showing reactivity with pemphigus antigens (Dsg1 and Dsg3) and desmocollins
11. Binding of autoantibodies is not restricted to desmosomes in pemphigus vulgaris; Comparison of 14 cases of pemphigus vulgaris and 10 cases of pemphigus foliaceus studied by Western immunoblot and immunoelectron microscopy
12. Molecular characterization of autoantibodies in pemphigus
13. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg 3) produced by baculovirus
14. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus
15. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity; Charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris
16. Development and characterization of desmoglein 3-specific T cells from patients with pemphigus vulgaris
17. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals
18. HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris. Review of the literature and potential applications for a specific immunotherapy
19. Peptide competition for antigen presentation
20. T cell receptor antagonists and partial agonists
21. Peptide-induced T cell tolerance to prevent autoimmune diabetes in a transgenic mouse model
22. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes
23. Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQw1 and DQw3 alleles of the HLA-D region
24. A newly characterized HLA-DQβ allele associated with pemphigus vulgaris
25. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3-specific T cell responses in pemphigus vulgaris patients and normals
26. Peptide binding specificity of HLA-DR4 molecules; Correlation with rheumatoid arthritis association
27. HLA-DQ polymorphisms are highly selective for peptide binding interactions
28. Individual effects of the DR11-variable β1-chain residues 67, 71, and 86 upon DR (alpha, β1*1101)-restricted, peptide-specific T cell proliferation
29. Desmoglein-1-specific T lymphocytes from patients with endemic pemphigus foliaceus (fogo selvagem)
30. Identification and characterization of autoreactive T cell responses to bullous pemphigoid (BP) antigen 2 in patients with BP and HLA-DQβ1*0301 positive normals
31. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice
32. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles
33. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris
34. Desmoglein 3 anchors telogen hair in the follicle
35. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus
36. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice
37. Immune modulation in pemphigus vulgaris; Role of CD28 and IL-10
38. In vitro and in vivo expression of interleukin-1alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris; Interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis
39. Induction of keratinocyte IL-8 expression and secretion by IgG autoantibodies as a novel mechanism of epidermal neutrophil recruitment in a pemphigus variant
40. Development of pemphigus vulgaris-like lesions in severe combined immunodeficiency disease mice with lymphocytes from patients
41. The humanized SCID mouse model to study HLA class II-linked autoimmunity to desmoglein 3 in pemphigus vulgaris